Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

finance.yahoo.com

Hoth Therapeutics receives IRB approval from Dana-Farber Cancer Institute and Montefiore Medical Center for Phase 2a clinical trial of HT-001 to treat skin toxicities from EGFRi.

stocktitan.net

Hoth Therapeutics receives IRB approval from Dana-Farber Cancer Institute and Montefiore Medical Center for Phase 2a clinical trial of HT-001 to treat skin toxicities from EGFRi, with $9 million in cash and no plans for further capital raise in 2024.